Amato F, et al. - The efficacy and tolerability of high-dose oxycodone-naloxone (OXN-PR) in chronic cancer pain were assessed. Even at high doses, OXN-PR was highly effective and well tolerated in cancer patients with chronic pain. As per the outcomes, the agonist-antagonist combination rapidly alleviated pain and its effect on life style, reducing the number of breakthrough cancer pain (BTCP) and improving opioid side effects.